Acorda Therapeutics Inc (ACORQ) Annual Income Statement

Annual · GAAP · USD millions
Access ACORQ quarterly income statements →
From Acorda Therapeutics Inc through Dec 31 2019, changes in Dec 31 2023's revenue and cost structure provide insight into profitability trends.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2023)
2023
(Dec 31 2022) (Dec 31 2021) (Dec 31 2020) (Dec 31 2019)
Revenues
Revenue From Contract With Customer Excluding Assessed Tax117.63
Total Revenue117.63
Costs & Expenses
Cost of Goods and Services Sold15.28
Gross Profit0.00
Selling, Administration, Marketing89.70
Depreciation & Amortization32.57
Research and Development Expense5.15
Restructuring, Accretion & Impairment Charges251.30
Other Operating Expense / -Income0.00
Total operating costs including COS0.00
Operating income / -loss-264.95
Interest Expense0.00
Net Interest Expense / -Income0.00
Extinguishment of Debt0.00
Investment Income, Interest0.53
Foreign Currency Transaction Gain (Loss), Realized-0.29
Other loss / -income0.00
Total costs & expenses382.59
Income & Taxes
Income / -loss before income taxes-296.02
Income taxes expenses / -benefit-43.17
Income after income taxes-252.85
Income / -loss from continuing operations-252.85
Net income / -loss-252.85
Income / -loss to shareholder-252.85
EBIT-296.02
EBITD-263.46
EBITDA-213.58
Earnings Per Share
Basic EPS (excl. extra items)-203.57
Basic Net EPS-203.57
Basic shares outstanding (Mill. of Units)1.24
Diluted Net EPS-203.57
Diluted average shares (Mill. of Units)1.24
4 historic quarters locked

Sign in to unlock the full Acorda Therapeutics Inc income statement history.

About Acorda Therapeutics Inc Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: April 1, 2024
  • Original filing: acor-20231231.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.